AngioDynamics (ANGO)
(Delayed Data from NSDQ)
$6.99 USD
+0.25 (3.71%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $6.99 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.99 USD
+0.25 (3.71%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $6.99 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth F Momentum D VGM
Zacks News
What's Sparking Market Futures? Big Q2 Results
by Mark Vickery
There is a bright, shining beacon markets appear to be attracted to currently: Q2 earnings season.
What's in Store for AngioDynamics (ANGO) in Q4 Earnings?
by Zacks Equity Research
AngioDynamics' (ANGO) expanding product pipeline, international market expansion and cost-saving initiatives to provide growth opportunities in Q4.
Why Is AngioDynamics (ANGO) Up 13.9% Since Its Last Earnings Report?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics (ANGO) Product Line Strong, Debt Level High
by Zacks Equity Research
AngioDynamics (ANGO) rides on promising NanoKnife performance. Dwindling sales are a concern.
AngioDynamics (ANGO) Beats on Q3 Earnings, Reiterates View
by Zacks Equity Research
AngioDynamics (ANGO) witnesses gross margin expansion and strong profits in the third quarter of fiscal 2018. However, lower sales in the company's RFA product line in Japan is a concern.
AngioDynamics Receives FDA Nod, to Treat Pancreatic Cancer
by Zacks Equity Research
AngioDynamics (ANGO) gets flagship NanoKnife designated with EAP.
AngioDynamics (ANGO) Banks on Buyouts, Debt Level High
by Zacks Equity Research
AngioDynamics (ANGO) continues to expand its business on the back of acquisitions and strategic alliances.
Zacks.com featured highlights include: AngioDynamics, Zumiez, GP Strategies, AngloGold and Raymond James
by Zacks Equity Research
Zacks.com featured highlights include: AngioDynamics, Zumiez, GP Strategies, AngloGold and Raymond James
Bet on These 5 PEG-Ratio Based GARP Picks
by Zacks Equity Research
A lower PEG ratio, preferably less than one, is always better for GARP investors.
AngioDynamics (ANGO) Misses on Earnings, Revenues in Q2
by Zacks Equity Research
Dwindling revenues in two major segments hurt AngioDynamics' (ANGO) second-quarter results.
Can AngioDynamics (ANGO) Pull a Surprise in Q2 Earnings?
by Zacks Equity Research
AngioDynamics (ANGO) to gain from solid product portfolio and demand for Solero MTA system. However, unfavorable estimates are a concern.
Why Is AngioDynamics (ANGO) Up 5.3% Since the Last Earnings Report?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamicis' (ANGO) Solero MTA System to Drive Growth
by Zacks Equity Research
Growth in the core Angiographic Catheter business is also likely to fortify the company's footprint in the global space.
AngioDynamics (ANGO) Misses on Earnings & Revenues in Q1
by Zacks Equity Research
AngioDynamics' (ANGO) adjusted gross margin decreased year over year owing to voluntary market withdrawal of the Acculis Microwave Tissue Ablation System.
Can AngioDynamics (ANGO) Spring a Surprise in Q1 Earnings?
by Zacks Equity Research
AngioDynamics (ANGO) is set to report first-quarter fiscal 2018 (ending Aug 31, 2017) results on Sep 28.
AngioDynamics' BioFlo Platform Strong, Debt Levels High
by Zacks Equity Research
AngioDynamics' (ANGO) exclusive Endexo technology in the BioFlo unit is expected to enhance the company's growth trajectory. However, high debt levels limit the company's core business strategies.
AngioDynamics (ANGO) Up 10.8% Since Earnings Report: Can It Continue?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics (ANGO) Shares Down Despite Q4 Earnings Beat
by Zacks Equity Research
AngioDynamics (ANGO) revenues declined year over year in the fourth quarter. Recall of the Acculis product line under the oncology segment is also a concern.
AngioDynamics (ANGO) Down 11.7% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics (ANGO) Prices 2.5M Secondary Share Offering
by Zacks Equity Research
AngioDynamics, Inc. (ANGO) announced that it has priced its underwritten public offering of 2.35 million shares of common stock.
5 Cheap Value Stocks to Tame a Capricious Market in Q2
by Zacks Equity Research
Given the volatile backdrop in the U.S. investment markets, we take a look at five companies which are great value bargains and poised for stellar gains in the second quarter that has just begun.
AngioDynamics (ANGO) Beats on Q3 Earnings, Raises 2017 View
by Zacks Equity Research
AngioDynamics Inc. (ANGO), a leading provider of minimally invasive medical devices, reported adjusted earnings of 19 cents per share in the third quarter of fiscal 2017.
Here's Why You Should Steer Clear of Mednax (MD) for Now
by Zacks Equity Research
Over the past 6 six months, shares of Mednax (MD) have gained 4.9%., underperforming the 9.8% increase logged by the Zacks categorized Medical - Hospital industry.
AngioDynamics Microwave Tissue Ablation System Now CE Marked
by Zacks Equity Research
AngioDynamics Inc. (ANGO), a leading provider of minimally invasive medical devices, recently announced the receipt of CE mark for Solero Microwave Tissue Ablation (MTA) System.
AngioDynamics (ANGO) Beats Q2 Earnings, Lifts 2017 View
by Zacks Equity Research
AngioDynamics Inc. (ANGO) reported adjusted earnings of 19 cents per share in the second quarter of fiscal 2017 beating the Zacks Consensus Estimate by 3 cents.